N/A N=1,076 Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students
SARS-CoV-2 · Serology · Students
Primary: Frequency of Handwashing — 412; 432; 65; 75 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=847 Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
COVID-19
Primary: Geometric Mean of Area Under the Curve (AUC) of Antibody Against WA-1 S2-P for Cohort 1 — 2940.97; 26101.97; 14223.28; 2926.70 Arbitrary Unit*1/dilution
N/A N=760 Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
SARS-CoV-2 · COVID-19
Primary: SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort — 15; 3; 16; 18 Participants
Phase 3 N=30 Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
Phase 1 N=135 Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
COVID-19 · COVID-19 Immunisation
Primary: Number of Participants With Any Medically-attended Adverse Events (MAAEs) — 1; 1; 0; 0 Participants
N/A N=1,361 Performance Evaluation of the Lucira COVID-19 & Flu Test
COVID-19 · Influenza
Primary: Confirmation That the Lucira COVID-19 & Flu Test Provides Similar Performance to a High Complexity Lab Molecular Diagnostic RT-PCR Assay(s) With Known High Sensitivity…
N/A N=230 The Role of Frequent Point-of-care Molecular Workplace Surveillance for Miners
Covid19
Primary: Number of Participants Screened (Molecular) — 169; 61 Participants
N/A N=792 COVID-19 Self-Testing Through Rapid Network Distribution
Covid19
Primary: Network Contact Test Uptake — 5; 2 Participants — p=0.45
Phase 3 N=1,323 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
Covid19 · SARS-CoV Infection
Primary: Clinical Progression to Severe Covid — 154; 179; 105; 96 Participants
N/A N=349 Motivation, Syringe Exchange, and COVID-19
COVID-19 Pandemic
Primary: SARS-CoV-2 Testing — 54; 53; 123; 119 Participants — p=.944
N/A N=40 Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic
COVID19
Primary: Number of Subjects for Which the Prototype Swab and the Control Swab Provide the Same COVID-19 PCR Result — 18; 17; 22; 23 participants
N/A N=4,142 COVID-19: Human Epidemiology and Response to SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
Phase 2 N=197 ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
COVID-19 Disease
Primary: Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 Index Virus Neutralizing Antibody Titers at 2 Weeks After the Last Vaccination — 516.7; 970.9; 978.9 titer
Phase 1 N=114 Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a
Covid19
Primary: Rate of Local Solicited Adverse Events After Each Study Vaccination — 13; 17; 11; 23 Participants
Phase 3 N=3,298 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
Healthy Participants
Primary: Cohort A: Percentage of Participants Who Have a Symptomatic RT-qPCR Confirmed SARS-CoV-2 Infection (Broad-term) During the EAP — 7.8; 1.4 Percentage of Participants…